AMLODIPINE - A REAPPRAISAL OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE IN CARDIOVASCULAR-DISEASE

被引:146
作者
HARIA, M
WAGSTAFF, AJ
机构
[1] Adis International Limited, Auckland, 65901, 41 Centorian Drive, Mairangi Bay
关键词
D O I
10.2165/00003495-199550030-00009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Amlodipine belongs to the dihydropyridine class of calcium channel blockers. Both short and long term studies indicate that amlodipine effectively lowers mild to moderately elevated blood pressure and relieves symptoms of angina pectoris. In comparative studies, its antihypertensive efficacy is similar to that of other established agents such as beta-blockers, diuretics, ACE inhibitors and other calcium channel blockers (including the dihydropyridines); limited comparative data are, however, available in patients with angina pectoris. Amlodipine may offer potential in patients with congestive heart failure. Vasodilator adverse events such as oedema, headaches, and flashing are commonly observed with amlodipine. The drug does not appear to cause postural hypotension, reflex tachycardia or cardiac conduction disturbances. Comparative studies suggest that amlodipine is at least as well tolerated as other standard agents. Thus, amlodipine provides an attractive therapeutic option for the treatment of hypertension, and offers potential for patients with angina pectoris. Its beneficial effects in patients with congestive heart failure require confirmation in future studies.
引用
收藏
页码:560 / 586
页数:27
相关论文
共 194 条
[1]   THE PHARMACOKINETIC PROFILE OF AMLODIPINE [J].
ABERNETHY, DR .
AMERICAN HEART JOURNAL, 1989, 118 (05) :1100-1103
[2]   EFFECTS OF AMLODIPINE, A LONG-ACTING DIHYDROPYRIDINE CALCIUM-ANTAGONIST IN AGING HYPERTENSION - PHARMACODYNAMICS IN RELATION TO DISPOSITION [J].
ABERNETHY, DR ;
GUTKOWSKA, J ;
WINTERBOTTOM, LM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 48 (01) :76-86
[3]   AMLODIPINE IN ELDERLY HYPERTENSIVE PATIENTS - PHARMACOKINETICS AND PHARMACODYNAMICS [J].
ABERNETHY, DR ;
GUTKOWSKA, J ;
LAMBERT, MD .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1988, 12 :S67-S71
[4]  
ADOLPHE AB, 1993, INT J CLIN PHARM RES, V13, P203
[5]  
Agabiti-Rosei E, 1994, J Cardiovasc Pharmacol, V24 Suppl A, pS37
[6]  
AMABILE G, 1994, ANN CARDIOL ANGEIOL, V43, P489
[7]  
ANTANI JA, 1994, J HYPERTENS S3, V12, P20
[8]   A COMPARATIVE-ASSESSMENT OF AMLODIPINE AND FELODIPINE ER - PHARMACOKINETIC AND PHARMACODYNAMIC INDEXES [J].
BAINBRIDGE, AD ;
HERLIHY, O ;
MEREDITH, PA ;
ELLIOTT, HL .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 45 (05) :425-430
[9]   DERMATOLOGICAL CROSS-SENSITIVITY BETWEEN DILTIAZEM AND AMLODIPINE [J].
BAKER, BA ;
CACCHIONE, JG .
ANNALS OF PHARMACOTHERAPY, 1994, 28 (01) :118-119
[10]   THE CALCIUM-CHANNEL BLOCKER AMLODIPINE RAISES SERUM DEHYDROEPIANDROSTERONE SULFATE AND ANDROSTENEDIONE, BUT LOWERS SERUM CORTISOL, IN INSULIN-RESISTANT OBESE AND HYPERTENSIVE MEN [J].
BEER, NA ;
JAKUBOWICZ, DJ ;
BEER, RM ;
NESTLER, JE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 76 (06) :1464-1469